

Mariacristina Di Marco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4057408/publications.pdf>

Version: 2024-02-01

48
papers

1,399
citations

471061

17
h-index

344852

36
g-index

53
all docs

53
docs citations

53
times ranked

2543
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene Panel. <i>Diagnostics</i> , 2022, 12, 1058.	1.3	4
2	Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes. <i>Cancers</i> , 2022, 14, 2429.	1.7	25
3	External validation of nomogram for predicting malignant intraductal papillary mucinous neoplasm (IPMN): from the theory to the clinical practice using the decision curve analysis model. <i>Updates in Surgery</i> , 2021, 73, 429-438.	0.9	3
4	The use of comprehensive complication Index® in pancreatic surgery: a comparison with the Clavien-Dindo system in a high volume center. <i>Hpb</i> , 2021, 23, 618-624.	0.1	10
5	The Italian Questionnaire for Cancer Breakthrough Pain Diagnosis, a Multicenter Validation Study. <i>Pain and Therapy</i> , 2021, 10, 1171-1188.	1.5	1
6	Neoadjuvant Therapy for Resectable Pancreatic Cancer. <i>Annals of Surgery</i> , 2021, 274, 713-720.	2.1	48
7	Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos. <i>Cancer Genetics</i> , 2020, 248-249, 57-62.	0.2	11
8	Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter caseâ€control study (PAULAâ€1). <i>Cancer Medicine</i> , 2020, 9, 7879-7887.	1.3	16
9	Intraoperative electrochemotherapy in locally advanced pancreatic cancer: indications, techniques and resultsâ€a single-center experience. <i>Updates in Surgery</i> , 2020, 72, 1089-1096.	0.9	16
10	How to Choose Between Percutaneous Transhepatic and Endoscopic Biliary Drainage in Malignant Obstructive Jaundice: An Updated Systematic Review and Meta-analysis. <i>In Vivo</i> , 2020, 34, 1701-1714.	0.6	23
11	Specific Toxicity of Maintenance Olaparib <i>Versus</i> Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis. <i>Anticancer Research</i> , 2020, 40, 597-608.	0.5	20
12	Higher Biologically Effective Dose Predicts Survival in SBRT of Pancreatic Cancer: A Multicentric Analysis (PAULA-1). <i>Anticancer Research</i> , 2020, 40, 465-472.	0.5	35
13	Searching for novel multimodal treatments in oligometastatic pancreatic cancer. <i>BMC Cancer</i> , 2020, 20, 271.	1.1	5
14	Long-term survival of two patients with recurrent pancreatic acinar cell carcinoma treated with radiofrequency ablation: A case report. <i>World Journal of Clinical Cases</i> , 2020, 8, 1241-1250.	0.3	5
15	Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 1456-1463.	0.8	2
16	Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. <i>Annals of Oncology</i> , 2019, 30, 1959-1968.	0.6	37
17	Pancreatic cyst surveillance imposes low psychological burden. <i>Pancreatology</i> , 2019, 19, 1061-1066.	0.5	8
18	Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival. <i>BMC Cancer</i> , 2019, 19, 569.	1.1	11

#	ARTICLE	IF	CITATIONS
19	What is the Outcome of Patients Affected by Intraductal Papillary Mucinous Neoplasms Without High-Risk Stigmata?. <i>Pancreas</i> , 2019, 48, 1167-1174.	0.5	2
20	Multicolour versus monocolour inking specimens after pancreaticoduodenectomy for periampullary cancer: A single centre prospective randomised clinical trial. <i>International Journal of Surgery</i> , 2018, 51, 63-70.	1.1	1
21	Î2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. <i>Cancer Cell</i> , 2018, 33, 75-90.e7.	7.7	287
22	Organizing pneumonia after pancreatic cancer treatment with nab-paclitaxel and gemcitabine: a case report. <i>BJR case Reports</i> , 2018, 4, 20170086.	0.1	2
23	Mutational burden of resectable pancreatic cancer, as determined by whole transcriptome and whole exome sequencing, predicts a poor prognosis. <i>International Journal of Oncology</i> , 2018, 52, 1972-1980.	1.4	8
24	Evaluation of fatigue in patients with pancreatic cancer receiving chemotherapy treatment: a cross-sectional observational study. <i>Acta Biomedica</i> , 2018, 89, 18-27.	0.2	12
25	Prospective validation of a preoperative risk score model based on pancreatic texture to predict postoperative pancreatic fistula after pancreaticoduodenectomy. <i>International Journal of Surgery</i> , 2017, 48, 189-194.	1.1	31
26	Nab-paclitaxel (Nab-P) and gemcitabine (G) first-line chemotherapy (CT) in patients (pts) with metastatic pancreatic cancer (mPC) who relapsed after adjuvant treatment (ADJ T): A "REAL LIFE" study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 396-396.	0.8	2
27	Risk Factors for Malignancy of Branch-Duct Intraductal Papillary Mucinous Neoplasms. <i>Pancreas</i> , 2016, 45, 1243-1254.	0.5	12
28	Retroperitoneal lymphangioma: A report of 2 cases and a review of the literature regarding the differential diagnoses of retroperitoneal cystic masses. <i>Oncology Letters</i> , 2016, 11, 3161-3166.	0.8	17
29	Is total pancreatectomy as feasible, safe, efficacious, and cost-effective as pancreaticoduodenectomy? A single center, prospective, observational study. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1595-1607.	0.9	38
30	Copy number gain of chromosome 3q is a recurrent event in patients with intraductal papillary mucinous neoplasm (IPMN) associated with disease progression. <i>Oncotarget</i> , 2016, 7, 74797-74806.	0.8	7
31	State of the art biological therapies in pancreatic cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 55.	0.8	30
32	Characterization of pancreatic ductal adenocarcinoma using whole transcriptome sequencing and copy number analysis by single-nucleotide polymorphism array. <i>Molecular Medicine Reports</i> , 2015, 12, 7479-7484.	1.1	20
33	Laparoscopic Versus Open Distal Pancreatectomy for Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 770-781.	0.9	105
34	Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 1802-1812.	0.9	166
35	Discovery of new potentially actionable mutations in pancreatic ductal adenocarcinoma by next generation sequencing.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4127-4127.	0.8	0
36	Antiprotease Strategy in Pancreatic Cancer Treatment. <i>Pancreas</i> , 2014, 43, 53-63.	0.5	3

#	ARTICLE	IF	CITATIONS
37	Influence of K-ras status and anti-tumour treatments on complications due to colorectal self-expandable metallic stents: A retrospective multicentre study. <i>Digestive and Liver Disease</i> , 2014, 46, 561-567.	0.4	16
38	Characterization of pancreatic ductal adenocarcinoma patients using whole-transcriptome sequencing and copy number analysis by SNPs array techniques.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15192-e15192.	0.8	0
39	Comparing recist and Choi's criteria to evaluate radiological response to chemotherapy in patients with advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15069-e15069.	0.8	4
40	Preoperative Gemcitabine and Oxaliplatin in a Patient with Ovarian Metastasis from Pancreatic Cystadenocarcinoma. <i>Case Reports in Gastroenterology</i> , 2012, 6, 530-537.	0.3	11
41	Hedgehog signaling: From the cuirass to the heart of pancreatic cancer. <i>Pancreatology</i> , 2012, 12, 388-393.	0.5	9
42	New WHO classification for pancreatic endocrine tumors: Is time to leave the previous one?. <i>Journal of Clinical Oncology</i> , 2012, 30, e14647-e14647.	0.8	0
43	Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancer: A literature review and report of two cases. <i>Oncology Letters</i> , 2011, 2, 195-200.	0.8	1
44	Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review). <i>Oncology Reports</i> , 2010, 23, 1183-92.	1.2	116
45	Exocrine-Endocrine Pancreatic Cancer and α -Fetoprotein. <i>Pancreas</i> , 2008, 37, 223-225.	0.5	8
46	Folate and prevention of colorectal cancer in ulcerative colitis. <i>European Journal of Cancer Prevention</i> , 2005, 14, 395-398.	0.6	17
47	Circadian variations of rectal cell proliferation in patients affected by advanced colorectal cancer. <i>Cancer Letters</i> , 2004, 208, 193-196.	3.2	17
48	Hypersensitivity reactions related to oxaliplatin (OHP). <i>British Journal of Cancer</i> , 2003, 89, 477-481.	2.9	113